Tuesday, November 22, 2011
Celldex Therapeutics Inc., of Needham, Mass., presented Phase II data showing rindopepimut (CDX-110) resulted in final overall survival of 24.6 months from diagnosis of EGFRvIII-positive glioblastoma, compared to 15.2 months for a historic control.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.